reports
Statement re Cancellation
Statement re Cancellation EASTPHARMA LTD (“the Company” or “Eastpharma”) EASTPHARMA’S DELISTING OF ITS GDRS Further to the Company's announcement of 2 May 2019, Eastpharma announces that the cancellation of the the standard listing of its Global Depositary Receipts (“GDRs”) on the Official List and the London Stock Exchange ("LSE") and the cancellation of the admission of the GDRs to trading on the main market of the LSE (the "LSE Delisting") is now effective as of 8.00 a.m.(London time) today, 1 August 2019. As a result of the above, the relationship agreement entered into at the time...
- Farida Salama
- Mariam Wael
- Mohamed Hamza
Annual General Meeting of EastPharma Ltd.
Annual General Meeting of EastPharma Ltd. EASTPHARMA LTD. London, 29 May 2019 - EastPharma (EAST LI), today announces that following todays's Annual General Meeting of EastPharma Ltd, the Board of EastPharma Ltd is pleased to announce that the resolutions for ordinary general assembly meeting proposed were duly passed by shareholders and all the information can be reached through EastPharma Ltd - a company active in manufacturing and marketing of pharmaceutical products in Turkey and in other regional markets; for further information please visit Attachment ...
- Mohamed Hamza
Egypt (Pharos): Eastern Tobacco Q3 18/19 – topline weakens sequentia...
EAST 3Q18/19 revenue increased by 4% YoY but fell 9% QoQ. Since the last price hike was implemented in July 2018, we believe the sequential drop in revenues is the result of slow volume growth, possibly due to weak purchasing power, or lower exports as a result of a stronger EGP/USD. The annual increase in revenues was mostly price-driven, where ASP went up by c.15% in July 2018.
Annual General Meeting of EastPharma Ltd.
Annual General Meeting of EastPharma Ltd. EASTPHARMA LTD. London, 02 May 2019 - EastPharma (EAST LI), today announces that the Annual General Meeting is to be held at 10.00 am on 29 May 2019 at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda. The formal notice of the Meeting and agenda for the Meeting are provided below and audited financial statements of the Company for the year ended 31 December 2018 is available for viewing on the company's website . EastPharma Ltd - a company active in the manufacturing and marketing of pharmaceutical products in Turkey and in o...
Statement re Cancellation
Statement re Cancellation NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION Certain information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (“MAR”). Upon publication of this Announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. The Company confirms that it currently h...
Statement re Cancellation
Statement re Cancellation NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION Certain information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (“MAR”). Upon publication of this Announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. The Company confirms that it currently has no...
- Farida Salama
- Radwa Elswaify
Egypt (Pharos): Consumers – Transition of coverage
This is a joint report from Exotix Capital and its research partner in Egypt, Pharos Holding. This report discontinues Exotix’s independent coverage of Juhayna. Please refer to Pharos’s Egypt equity strategy for their views on Egypt’s consumer sector.
Statement re Cancellation
Statement re Cancellation NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION Certain information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (“MAR”). Upon publication of this Announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. The Company confirms that it currently ha...
Statement re Cancellation
Statement re Cancellation NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION Certain information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (“MAR”). Upon publication of this Announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. The Company confirms that it currently ha...
Audited Financial Statements' Announcement for The Year Ended 31 Decem...
Audited Financial Statements' Announcement for The Year Ended 31 December 2018 EASTPHARMA LTD. London, 8 March 2019 - EASTPHARMA (EAST LI) announces that it is releasing its audited financial statements for the year ended 31 December 2018 and a review of its main subsidiary DEVA Holding's audited financial statements for the related period. Management comment on the financial performance of EASTPHARMA is provided in the attachment, and a presentation of the results will be available on the EASTPHARMA website on 11 March 2019. A conference call to review the financial performance fo...
Advance Notice: Audited Financial Statements' Announcement for The Yea...
Advance Notice: Audited Financial Statements' Announcement for The Year Ended 31 December 2018 EASTPHARMA LTD. London, 1 March 2019 - EastPharma (EAST LI) informs that it will be releasing its audited financial statements for the year ended 31 December 2018 and a review of its main subsidiary DEVA Holding's audited financial statements for the related period on 8 March 2019. A conference call to review the financial performance for the year ended 31 December 2018 will be hosted by the management of EastPharma at 12:00-noon London time on 11 March 2019 (08:00am New York time / 01:00-pm Z...
- Mohamed Hamza
Egypt (Pharos): EAST – Sequential recovery in volumes; interest inco...
Eastern Tobacco (EAST) witnessed revenue increase by 2% YoY and 9% QoQ in Q2 18/19. The slow growth in annual revenues comes despite the enacted prices increases, where the latest price hikes of c.15% were implemented in July 2018. Sequential recovery was mostly volume-driven, where volumes seem to have picked up after being negatively impacted by the price increases.
- Mohamed Hamza
Egypt (Pharos): Eastern Tobacco – price-driven story, clouded by ope...
We downgrade our FV to EGP19.80/share due to 1) increasing employees’ profit share distributions; 2) decreasing excess cash balance from EGP4.8 billion reported in September 2018 by EGP3.0 billion, which belong to the Ministry of Finance representing VAT, and which reduced the net cash position to EGP1,784 billion in our FV calculation.
NOTIFICATION OF CHANGE IN SHAREHOLDING
NOTIFICATION OF CHANGE IN SHAREHOLDING 11 September 2018 Certain information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (“MAR”). Upon publication of this Announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. The Company confirms that it currently has no unpublished price sensitive information. EASTPHARMA LTD("the Company") NOTIFICATION OF CHANGE IN SHAREHOLDING In conformity with the di...
Reviewed Financial Statement's announcement for the period 30 June 201...
Reviewed Financial Statement's announcement for the period 30 June 2018 EASTPHARMA LTD. London, 13 August 2018 - EastPharma (EAST LI) announces that it is releasing its reviewed financial statements for the period 30 June 2018 and a review of its main subsidiary DEVA Holding's financial statements for the related period. Management comment on the financial performance of EastPharma is provided in the attachment, and a presentation of the results will be available on the EastPharma website on 14 August 2018. A conference call to review the financial performance for the period ende...
Advance Notice: Reviewed Financial Statement's announcement for the pe...
Advance Notice: Reviewed Financial Statement's announcement for the period 30 June 2018 EASTPHARMA LTD. London, 08 August 2018 - EastPharma (EAST LI) informs that it will be releasing its reviewed financial statements for the period 30 June 2018 and a review of its main subsidiary DEVA Holding's financial statements for the related period on 13 August 2018. A conference call to review the financial performance for the period ended 30 June 2018 will be hosted by the management of EastPharma at 11:00am London time on 14 August 2018 (06:00am New York time / 12:00-noon Zur...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Stunning performance
During the third quarter of the year, sales grew by 9.3% to EGP5.725bn vs. EGP5.236bn, a year ago. The tobacco monopoly’s profits stood at EGP1.08bn, up by 28.3%, yoy. The EBITDA margin was up by 20 bp to 28%. Also, the net margin reached 18.86% by the end of March 2016 vs. 16.07% a year ago.
EASTERN and growth, the inseparables
Eastern released its H1 2015/16 figures. The Egyptian leader achieved impressive results exceeding our 2015/16 profit targets. The net profit amounted to EGP809M, up by 38.1%, yoy (vs. EGP1.279bn expected by our model for the whole year). Eastern lifted its sales by 12.5% to EGP3.877bn. During the second quarter of the year, the EBITDA surged by 22.5% to reach EGP1.141bn vs. EGP932.099M by the end of December, 2014.Thus, the EBITDA margin increased significantly by 240 bps to 29.4%.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.